Vantage logo

Calithera buys itself a plan B

With telaglenastat facing a risky trial readout Calithera picks up two bargain-basement oncology projects to pivot to.

Vantage logo

Treme climbs a new mountain

Astrazeneca’s Himalaya study is a surprising hit in first-line liver cancer, but competition is already present.

Vantage logo

Atara claims a remyelination signal

The company’s off-the-shelf T-cell immunotherapy seems to be improving multile sclerosis disability, but an ongoing phase 2 trial will provide a better test.